Metagenomi Therapeutics, Inc.

MGX Nasdaq SEC CIK 1785279
Follow Metagenomi Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.2M −74.8% vs same quarter last year
Net income −$21.1M −3.6% vs same quarter last year
EPS, diluted −$0.56 −1.8% vs same quarter last year
Operating cash flow −$19.1M +10.2% vs same quarter last year
Revenue by quarter
$9.6M
$4.1M
$8.5M
$8.7M
$3.9M
$1.2M
$2.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$25.2M−$87.9M
FY24$52.3M−$78.1M
FY23$44.8M−$68.3M
FY22--
MarginsShare of revenue
  • Operating margin
  • Net margin
−400%−300%−200%−100%0%FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−380.9%−348.5%
FY24−170%−149.3%
FY23−175.4%−152.5%
FY22--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$89.5M
FY24−$112.2M
FY23−$101.2M
FY22-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Metagenomi Therapeutics
  • Healthcare median
−400%−300%−200%−100%0%FY22FY23FY24FY25
Show the numbers
YearMetagenomi TherapeuticsHealthcare median
FY25−348.5%−30.6%
FY24−149.3%−47%
FY23−152.5%−58%
FY22-−80.4%